One-year open-label safety and efficacy study of paliperidone extended-release

CNS Spectrums

Volumn 15, Issue 8, 2010, Pages 506-514

  Kramer, Michelle ^a   Simpson, George ^a   Maciulis, Valentinas ^a   Kushner, Stuart ^a   Liu, Yanning ^a   Lim, Pilar ^a   Hough, David ^a   Palumbo, Joseph ^a   Eerdekens, Mariëlle ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELAYED RELEASE FORMULATION; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PALIPERIDONE; TABLET;

CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; HUMAN; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TABLET;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; HUMANS; ISOXAZOLES; PALIPERIDONE PALMITATE; SCHIZOPHRENIA; TABLETS;

EID: 77956117157     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900000456     Document Type: Article

References (13)

1. Mancevski B, Keilp J, Kurzon M, et al. Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia. Psychopathology. 2007;40(2):83-92.
2. Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67(10):1542-1550.
3. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005; 3:21.
4. Yamada K, Watanabe K, Nemoto N, et al. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Psychiatry Res. 2006;141(1):61-69.
5. Cooper C, Bebbington P, King M, et al. Why people do not take their psychotropic drugs as prescribed: results of the 2000 National Psychiatric Morbidity Survey. Acta Psychiatr Scand. 2007;116(1):47-53.
6. Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophr Res. 2006;81(Suppl 1):85-86.
7. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1-3):147-161.
8. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1-3):117-130.
9. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended release tablets for prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(1):6-14.
10. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
11. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-546.
12. Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S29-S35.
13. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999;46(10):1396-1408.